Women’s healthcare major Hologic Inc. (HOLX) will showcase the benefits of its leading-edge 3D mammography systems at the 23rd Annual National Interdisciplinary Breast Cancer Conference in Las Vegas hosted by the National Consortium of Breast Cancer (NCBC).
The company will resort to a mobile coach tour at the conference to expand its reach. The innovative initiative dubbed ‘3D Technology: A More Accurate Mammogram’ should publicize the clinical benefits of its 3D mammography systems to the medical community and target population. According to the company, a mobile configuration will increase the scope of its critical screening tool for women who otherwise do not have the access to technically advanced systems for breast imaging.
Results from clinical studies demonstrate the efficacy of Hologic’s well-regarded technology as its 3D mammography in conjunction with the routine 2D imaging improves detection of cancer. It also decreases the need for callbacks as shown by the findings from the study titled Comparison of Digital Mammography Alone and Digital Mammography Plus Tomosynthesis in a Population-based Screening Program. The increase in detection rate and decrease in the need for callbacks is crucial for women with restricted access to annual screening mammography.
Although mortality rate from breast cancer declined 31% since 1990 on the heels of higher detection rates with mammographic screening, more than 40% American women still undergo only regular screening. This is mainly due to lack of easy access for these women. Hologic’s mobile mammography addresses this issue by enabling point-of-care mammographic screening for women.
Apart from its 3D mammography systems, the company will also display its Advanced Body Composition Assessment package for the osteoporosis assessment system, new tomosynthesis biopsy option to be used on the Affirm biopsy guidance system. Hologic also plans to showcase its CE marked synthesized 2D (C-View) images.
Offering a wide range of products, Hologic is arguably an industry leader in the field of women’s health. Going forward, we are optimistic about increasing uptake of the company’s technically advanced solutions.
The stock carries a Zacks Rank #3 (Hold). Although we remain on the sidelines for Hologic, we believe that other medical stocks such as Abaxis (ABAX), Conceptus (CPTS) and Cyberonics (CYBX) are likely to do well. These stocks carry a Zacks Rank #2 (Buy) each.
More From Zacks.com